BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...Northwestern University describes a new therapeutic to deplete GPX4. The researchers designed functional lipoprotein-like nanoparticles (Flip-NPs...
...deplete cholesterol in the cell membrane, leading to a reduction in GPX4 expression and ferroptosis. Flip-NPs...
BioCentury | May 17, 2019
Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

...indication. Takeda's Shire plc unit gained the analog of GLP-2 through its 2015 acquisition of NPS Pharmaceuticals Inc....
BioCentury | Apr 18, 2019
Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

...also venture partner at Blackstone, will join the company's board along with former CEO of NPS Pharmaceuticals Inc....
BioCentury | Oct 20, 2017
Clinical News

EC approves Amgen's Mimpara for pediatric indication

...has rights outside of China, Japan, North and South Korea and Taiwan to cinacalcet from NPS Pharmaceuticals Inc....
...plc (LSE:SHP; NASDAQ:SHPG) acquired. Kyowa has rights in the Asian countries from a deal with NPS...
BioCentury | Jul 18, 2017
Distillery Techniques

Drug delivery; drug platforms

...nanoparticles (AC-NPs) could enhance immune responses to radiotherapy plus checkpoint inhibitors to treat cancer. The AC-NPs...
...tumor cells after radiotherapy-induced cell death. In xenograft mouse models of melanoma and breast cancer, AC-NPs...
...survival compared with free tumor antigens plus radiotherapy and the antibody. In the melanoma model, AC-NPs...
BioCentury | Jul 7, 2017
Clinical News

EMA's CHMP recommends pediatric label expansion for Amgen's Mimpara

...has rights outside of China, Japan, North and South Korea and Taiwan to cinacalcet from NPS Pharmaceuticals Inc....
...plc (LSE:SHP; NASDAQ:SHPG) acquired. Kyowa has rights in the Asian countries from a deal with NPS...
BioCentury | Jan 26, 2017
Translation in Brief

Pickpocketed orphans

...related to several other receptors, including orexin ( hypocretin ; HCRT ) and neuropeptide S (NPS...
BioCentury | Oct 27, 2015
Company News

PTAB institutes IPRs of Bass' Gattex petitions

...patents covering Gattex. The last expires in 2025. Shire gained Gattex through its acquisition of NPS Pharmaceuticals Inc....
BioCentury | Sep 17, 2015
Distillery Techniques

Techniques: RNA transcripts nanoparticles (RNAtr NPs) for tumor-targeted siRNA delivery

...Drug delivery TECHNOLOGY: Nanoparticles RNA transcripts nanoparticles (RNAtr NPs) could be used to deliver siRNA to...
...testing RNAtr NP-based delivery of therapeutic siRNAs in tumor models. DESCRIPTION: RNA transcripts nanoparticles (RNAtr NPs...
BioCentury | Sep 14, 2015
Politics, Policy & Law

IPR battles

...IPR petition filed by Bass' Coalition for Affordable Drugs LLC against a patent held by NPS...
...on several questions related to the legality of IPR challenges like those Bass has filed. NPS...
...intended solely to create short-term trading opportunities and should be prohibited. In addition to the NPS...
Items per page:
1 - 10 of 671
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...Northwestern University describes a new therapeutic to deplete GPX4. The researchers designed functional lipoprotein-like nanoparticles (Flip-NPs...
...deplete cholesterol in the cell membrane, leading to a reduction in GPX4 expression and ferroptosis. Flip-NPs...
BioCentury | May 17, 2019
Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

...indication. Takeda's Shire plc unit gained the analog of GLP-2 through its 2015 acquisition of NPS Pharmaceuticals Inc....
BioCentury | Apr 18, 2019
Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

...also venture partner at Blackstone, will join the company's board along with former CEO of NPS Pharmaceuticals Inc....
BioCentury | Oct 20, 2017
Clinical News

EC approves Amgen's Mimpara for pediatric indication

...has rights outside of China, Japan, North and South Korea and Taiwan to cinacalcet from NPS Pharmaceuticals Inc....
...plc (LSE:SHP; NASDAQ:SHPG) acquired. Kyowa has rights in the Asian countries from a deal with NPS...
BioCentury | Jul 18, 2017
Distillery Techniques

Drug delivery; drug platforms

...nanoparticles (AC-NPs) could enhance immune responses to radiotherapy plus checkpoint inhibitors to treat cancer. The AC-NPs...
...tumor cells after radiotherapy-induced cell death. In xenograft mouse models of melanoma and breast cancer, AC-NPs...
...survival compared with free tumor antigens plus radiotherapy and the antibody. In the melanoma model, AC-NPs...
BioCentury | Jul 7, 2017
Clinical News

EMA's CHMP recommends pediatric label expansion for Amgen's Mimpara

...has rights outside of China, Japan, North and South Korea and Taiwan to cinacalcet from NPS Pharmaceuticals Inc....
...plc (LSE:SHP; NASDAQ:SHPG) acquired. Kyowa has rights in the Asian countries from a deal with NPS...
BioCentury | Jan 26, 2017
Translation in Brief

Pickpocketed orphans

...related to several other receptors, including orexin ( hypocretin ; HCRT ) and neuropeptide S (NPS...
BioCentury | Oct 27, 2015
Company News

PTAB institutes IPRs of Bass' Gattex petitions

...patents covering Gattex. The last expires in 2025. Shire gained Gattex through its acquisition of NPS Pharmaceuticals Inc....
BioCentury | Sep 17, 2015
Distillery Techniques

Techniques: RNA transcripts nanoparticles (RNAtr NPs) for tumor-targeted siRNA delivery

...Drug delivery TECHNOLOGY: Nanoparticles RNA transcripts nanoparticles (RNAtr NPs) could be used to deliver siRNA to...
...testing RNAtr NP-based delivery of therapeutic siRNAs in tumor models. DESCRIPTION: RNA transcripts nanoparticles (RNAtr NPs...
BioCentury | Sep 14, 2015
Politics, Policy & Law

IPR battles

...IPR petition filed by Bass' Coalition for Affordable Drugs LLC against a patent held by NPS...
...on several questions related to the legality of IPR challenges like those Bass has filed. NPS...
...intended solely to create short-term trading opportunities and should be prohibited. In addition to the NPS...
Items per page:
1 - 10 of 671